Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (151-160 of 391) with videos related to

Pageof 40
Sort By:
American Journal of Respiratory and Critical Care Medicine|January 12, 2021
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary FibrosisMichael Kreuter, Joyce S Lee, Argyrios Tzouvelekis, et al.
The European Respiratory Journal|July 10, 2019
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseasesLutz Wollin, Jörg H W Distler, Elizabeth F Redente, et al.
NEJM Evidence|February 6, 2024
Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary FibrosisToby M Maher, Cristina Avram, Enoch Bortey, et al.
ERJ Open Research|December 17, 2024
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosisR Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, et al.
Respiratory Research|February 1, 2020
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trialsMichael Kreuter, Wim A Wuyts, Marlies Wijsenbeek, et al.
Respiration; International Review of Thoracic Diseases|July 20, 2018
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary FibrosisPaolo Spagnolo, Michael Kreuter, Toby M Maher, et al.
The American Journal of Pathology|January 17, 2009
Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q)Ming Yan Xu, Joanne Porte, Alan J Knox, et al.
The European Respiratory Journal|November 17, 2018
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidoneLuca Richeldi, Sophie Fletcher, Huzaifa Adamali, et al.
Respiratory Medicine|November 8, 2016
Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predictedKatie Ward, Lydia Spurr, Nina R Goldman, et al.
American Journal of Respiratory and Critical Care Medicine|April 7, 2018
Rapidly Progressive Cystic Lung DiseaseCharlotte Rogers, James Kent-Bramer, Anand Devaraj, et al.
Pageof 40

Showing results (151-160 of 391) with videos related to

Sort By:
Pageof 40
American Journal of Respiratory and Critical Care Medicine|January 12, 2021
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary FibrosisMichael Kreuter, Joyce S Lee, Argyrios Tzouvelekis, et al.
The European Respiratory Journal|July 10, 2019
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseasesLutz Wollin, Jörg H W Distler, Elizabeth F Redente, et al.
NEJM Evidence|February 6, 2024
Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary FibrosisToby M Maher, Cristina Avram, Enoch Bortey, et al.
ERJ Open Research|December 17, 2024
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosisR Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, et al.
Respiratory Research|February 1, 2020
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trialsMichael Kreuter, Wim A Wuyts, Marlies Wijsenbeek, et al.
Respiration; International Review of Thoracic Diseases|July 20, 2018
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary FibrosisPaolo Spagnolo, Michael Kreuter, Toby M Maher, et al.
The American Journal of Pathology|January 17, 2009
Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q)Ming Yan Xu, Joanne Porte, Alan J Knox, et al.
The European Respiratory Journal|November 17, 2018
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidoneLuca Richeldi, Sophie Fletcher, Huzaifa Adamali, et al.
Respiratory Medicine|November 8, 2016
Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predictedKatie Ward, Lydia Spurr, Nina R Goldman, et al.
American Journal of Respiratory and Critical Care Medicine|April 7, 2018
Rapidly Progressive Cystic Lung DiseaseCharlotte Rogers, James Kent-Bramer, Anand Devaraj, et al.
Pageof 40